Differential effects of benzodioxane, chroman and dihydrobenzofuran analogs of clofibrate in a Triton hyperlipemic rat model.
D000818:Animals; D000924:Anticholesteremic Agents / Q000494:pharmacology; D001555:Benzene Derivatives / Q000494:pharmacology; D001572:Benzofurans / Q000494:pharmacology*; D001578:Benzopyrans / Q000494:pharmacology*; D002264:Carboxylic Acids / Q000494:pharmacology; D002784:Cholesterol / Q000097:blood; D002994:Clofibrate / Q000494:pharmacology*; D003720:Densitometry; D004147:Dioxins / Q000494:pharmacology*; D004195:Disease Models, Animal; D004586:Electrophoresis; D004952:Esters / Q000494:pharmacology; D006949:Hyperlipidemias / Q000097:blood* / Q000139:chemically induced; D000960:Hypolipidemic Agents / Q000494:pharmacology; D008055:Lipids / Q000097:blood*; D008074:Lipoproteins / Q000097:blood / Q000302:isolation & purification; D008297:Male; D051381:Rats; D013329:Structure-Activity Relationship; D013501:Surface-Active Agents; D014280:Triglycerides / Q000097:blood
D000924:Anticholesteremic Agents; D001555:Benzene Derivatives; D001572:Benzofurans; D001578:Benzopyrans; D002264:Carboxylic Acids; D004147:Dioxins; D004952:Esters; D000960:Hypolipidemic Agents; D008055:Lipids; D008074:Lipoproteins; D013501:Surface-Active Agents; D014280:Triglycerides; D002784:Cholesterol; D002994:Clofibrate